Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1949826

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1949826

Biologics Manufacturing Global Market Report 2026

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4490
PDF & Excel (Site License)
USD 6490
PDF & Excel (Enterprise License)
USD 8490

Add to Cart

Biologics manufacturing involves the intricate production of medications sourced from living organisms or their parts. It entails growing genetically modified cells or microbes in bioreactors to produce therapeutic proteins or other biologic substances, then applying purification methods such as filtration and chromatography to guarantee safety and purity. This approach facilitates the creation of secure, potent, and superior biologic therapies, advancing personalized treatments and enhancing patient results.

The primary approaches to biologics production are contract manufacturing and in-house manufacturing. Contract manufacturing involves a company outsourcing the production of its biologic products to a specialized third-party provider. Key modalities encompass monoclonal antibodies (mAbs), biosimilars and recombinant proteins, vaccines, cell and gene therapies, and RNA-based therapeutics, targeting oncology, autoimmune conditions, infectious diseases, neurological disorders, and various other indications.

Tariffs are affecting the biologics manufacturing market by increasing costs of imported bioreactors, chromatography resins, filtration membranes, sensors, and automation systems essential for upstream and downstream processing. Manufacturing facilities in North America and Europe are most impacted due to reliance on imported high-end bioprocess equipment, while Asia-Pacific faces higher costs for export-focused production expansion. These tariffs are elevating capital investment requirements and extending facility commissioning timelines. However, they are also promoting domestic equipment manufacturing, regional supply chain strengthening, and increased adoption of locally sourced bioprocess technologies.

The biologics manufacturing market research report is one of a series of new reports from The Business Research Company that provides biologics manufacturing market statistics, including biologics manufacturing industry global market size, regional shares, competitors with a biologics manufacturing market share, detailed biologics manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics manufacturing industry. This biologics manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biologics manufacturing market size has grown exponentially in recent years. It will grow from $42.04 billion in 2025 to $50.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to expansion of recombinant protein therapeutics, early adoption of mammalian cell culture systems, growth in vaccine manufacturing capacity, increasing outsourcing of biologics production, advancements in purification technologies.

The biologics manufacturing market size is expected to see exponential growth in the next few years. It will grow to $106.08 billion in 2030 at a compound annual growth rate (CAGR) of 20.3%. The growth in the forecast period can be attributed to increasing demand for personalized biologics, rising investments in flexible manufacturing platforms, expansion of biosimilar development, growing adoption of digital bioprocessing tools, focus on cost-efficient large-scale production. Major trends in the forecast period include increasing adoption of single-use bioprocessing systems, rising deployment of continuous biomanufacturing, growing demand for high-volume monoclonal antibody production, expansion of modular biologics facilities, enhanced integration of advanced process control.

The increasing incidence of chronic diseases is anticipated to fuel expansion in the biologics manufacturing market. Chronic diseases represent long-term health issues that progress gradually and persist over time, frequently demanding ongoing medical attention. This surge stems in part from sedentary lifestyles, where extended periods of sitting and limited exercise heighten the chances of ailments like cardiovascular disease and diabetes. Biologics manufacturing supports chronic disease treatment through the creation of precise therapies, proving highly effective for managing diabetes, cancer, and autoimmune conditions. It alleviates the overall disease load by delivering reliable, top-quality biologic drugs, which enhance patient results and optimize therapeutic processes. For instance, in June 2024, the National Health Service-a UK government agency-reported that 3,615,330 patients registered with general practitioners (GPs) had been diagnosed with non-diabetic hyperglycemia or pre-diabetes (elevated blood sugar not severe enough for a diabetes diagnosis) in 2023, reflecting an 18% rise from 3,065,825 cases the previous year. Thus, the escalating prevalence of chronic diseases is propelling the biologics manufacturing market forward.

Major companies in the biologics manufacturing sector are prioritizing the creation of cutting-edge solutions, including unified biologics contract development and manufacturing organization (CDMO) platforms, to streamline comprehensive biologics development, boost production efficiency, and improve supply chain coordination across diverse therapeutic areas. An integrated biologics CDMO platform represents a holistic system that merges biologics development, manufacturing, and supply services into one cohesive framework. For example, in June 2023, Catalent Inc., a US-based contract development and manufacturing firm, broadened its OneBio Suite to deliver integrated development, manufacturing, and supply capabilities for various biologic modalities. The upgraded OneBio Suite introduces a complete biologics CDMO platform supporting antibodies, cell and gene therapies, and mRNA products. It delivers full-spectrum services from development through fill-finish and packaging under a single contract with consistent project management, facilitating quicker timelines, greater scalability, and smooth global supply chain connectivity.

In September 2025, Terumo Corporation, a Japan-based medical technology firm, purchased WuXi Biologics (Cayman) Inc. for an undisclosed sum. This acquisition allows Terumo to boost its CDMO production capabilities and worldwide footprint, strengthening its capacity to deliver comprehensive biologics manufacturing and fill-finish services for injectable treatments. WuXi Biologics (Cayman) Inc., headquartered in China, provides full-spectrum solutions for biologics discovery, development, and production.

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biologics manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics manufacturing market consists of sales of therapeutic proteins, enzymes, recombinant DNA products, blood factors, and other biologic-based therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologics Manufacturing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biologics manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologics manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biologics manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Mode of Manufacturing: Contract Manufacturing; In-House Manufacturing
  • 2) By Modality: Monoclonal Antibodies (mAbs); Biosimilar And Recombinant Proteins; Vaccines (recombinant/mRNA/Viral); Cell And Gene Therapies; Ribonucleic Acid-Based Therapeutics
  • 3) By Disease Indication: Oncology; Autoimmune Disorders; Infectious Diseases; Neurological Disorders; Other Disease Indications
  • Subsegments:
  • 1) By Contract Manufacturing: Mammalian Cell-Based Production; Microbial Fermentation Production; Cell-Free Protein Synthesis; Hybrid Manufacturing Systems
  • 2) By In-House Manufacturing: Mammalian Cell Culture Production; Microbial Expression Systems; Continuous Bioprocessing; Single-Use Technology Production
  • Companies Mentioned: Johnson & Johnson; F. Hoffmann La-Roche Ltd.; Pfizer Inc; AbbVie Inc.; Eli Lilly and Company; Novartis AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; LG Life Sciences Ltd.; Novo Nordisk A/S; Amgen Inc.; FUJIFILM Holdings Corporation; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Lonza Group Ltd.; Intas Pharmaceuticals Ltd.; Samsung Biologics Co. Ltd.; Fareva SA; Celltrion Inc.; Evotec SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MBMAN02_G26Q1

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Biologics Manufacturing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Biologics Manufacturing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Biologics Manufacturing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Biologics Manufacturing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 5+Dg40:Dg46
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
    • 4.1.5 Artificial Intelligence & Autonomous Intelligence
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Single-Use Bioprocessing Systems
    • 4.2.2 Rising Deployment Of Continuous Biomanufacturing
    • 4.2.3 Growing Demand For High-Volume Monoclonal Antibody Production
    • 4.2.4 Expansion Of Modular Biologics Facilities
    • 4.2.5 Enhanced Integration Of Advanced Process Control

5. Biologics Manufacturing Market Analysis Of End Use Industries

  • 5.1 Biopharmaceutical Companies
  • 5.2 Contract Manufacturing Organizations
  • 5.3 Vaccine Manufacturers
  • 5.4 Biotechnology Firms
  • 5.5 Research Institutes

6. Biologics Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Biologics Manufacturing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Biologics Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Biologics Manufacturing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Biologics Manufacturing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Biologics Manufacturing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Biologics Manufacturing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Biologics Manufacturing Market Segmentation

  • 9.1. Global Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Contract Manufacturing, In-House Manufacturing
  • 9.2. Global Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics
  • 9.3. Global Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications
  • 9.4. Global Biologics Manufacturing Market, Sub-Segmentation Of Contract Manufacturing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems
  • 9.5. Global Biologics Manufacturing Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production

10. Biologics Manufacturing Market Regional And Country Analysis

  • 10.1. Global Biologics Manufacturing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Biologics Manufacturing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Biologics Manufacturing Market

  • 11.1. Asia-Pacific Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Biologics Manufacturing Market

  • 12.1. China Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Biologics Manufacturing Market

  • 13.1. India Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Biologics Manufacturing Market

  • 14.1. Japan Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Biologics Manufacturing Market

  • 15.1. Australia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Biologics Manufacturing Market

  • 16.1. Indonesia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Biologics Manufacturing Market

  • 17.1. South Korea Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Biologics Manufacturing Market

  • 18.1. Taiwan Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Biologics Manufacturing Market

  • 19.1. South East Asia Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Biologics Manufacturing Market

  • 20.1. Western Europe Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Biologics Manufacturing Market

  • 21.1. UK Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Biologics Manufacturing Market

  • 22.1. Germany Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Biologics Manufacturing Market

  • 23.1. France Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Biologics Manufacturing Market

  • 24.1. Italy Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Biologics Manufacturing Market

  • 25.1. Spain Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Biologics Manufacturing Market

  • 26.1. Eastern Europe Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Biologics Manufacturing Market

  • 27.1. Russia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Biologics Manufacturing Market

  • 28.1. North America Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Biologics Manufacturing Market

  • 29.1. USA Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Biologics Manufacturing Market

  • 30.1. Canada Biologics Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Biologics Manufacturing Market

  • 31.1. South America Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Biologics Manufacturing Market

  • 32.1. Brazil Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Biologics Manufacturing Market

  • 33.1. Middle East Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Biologics Manufacturing Market

  • 34.1. Africa Biologics Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Segmentation By Modality, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Biologics Manufacturing Market Regulatory and Investment Landscape

36. Biologics Manufacturing Market Competitive Landscape And Company Profiles

  • 36.1. Biologics Manufacturing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Biologics Manufacturing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Biologics Manufacturing Market Company Profiles
    • 36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. F. Hoffmann La-Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Biologics Manufacturing Market Other Major And Innovative Companies

  • Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

38. Global Biologics Manufacturing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Biologics Manufacturing Market

40. Biologics Manufacturing Market High Potential Countries, Segments and Strategies

  • 40.1 Biologics Manufacturing Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Biologics Manufacturing Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Biologics Manufacturing Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!